Outline
Mission: to “realize the application of human iPSC-derived cardiomyocytes, hepatocytes and neurons for drug safety evaluations by both technological advancement and including policy recommendations.”
Organizational structure
» Total 61 Companies/Facilities/Organization (As of Aug. 10th, 2021)
An Executive Committee
| Consortium Leader | Norimasa Miyamoto, Ph.D. (Eisai Co., Ltd.) |
| Cardiomyocyte Team Leader | Kiyoshi Takashuna, Ph.D. (Axcelead Drug Discovery Partners Inc.) |
| Neuron Team Leader | Takafumi Shirakawa, Ph.D. (Astellas Pharma Inc.) |
| Neuron Team Subleader | Takuya Kondo, Ph.D. (TAIHO PHARMACEUTICAL CO., LTD.) |
| Neuron Team in vivo Group Leader | Kaoru Morimura, Ph.D. (FUJIFILM Corporation) |
| Neuron Team Data Analysis Group Leader | Takayoshi Matsubara (PerkinElmer Japan Co., Ltd.) |
| Cell Characterization Team Leader | Toshikatsu Matsui, Ph.D. (Takeda Pharmaceutical Company Limited) |
| Information Sharing Leader | Tomoharu Osada, Ph.D.（LSI Medience Corporation） |
| Information Sharing Subleader | Atsuko Ojima（TechnoPro, Inc. TechnoPro R&D, Company） |
| MPS Team Leader | Hitoshi Naraoka (Astellas Pharma Inc.) |
